{
  "analyst_run_id": "RUN-20260715-600276-20260715060112632998-dca54466",
  "decision": {
    "chase_limit": null,
    "decision": "WAIT",
    "entry_max": null,
    "entry_min": null,
    "invalid_conditions": [
      "八维分析存在失败或缺失维度"
    ],
    "main_theme": "创新药",
    "position_limit": 0.0,
    "raw": {
      "decision": "WAIT",
      "evidence_ids": [],
      "invalid_conditions": [
        "八维分析存在失败或缺失维度"
      ],
      "main_theme": "创新药",
      "position_limit": 0,
      "risk_notes": [
        "必须补齐全部八维报告"
      ],
      "score": 48.36,
      "setup": "LOW_VOLUME_BREAKOUT",
      "stock_name": "恒瑞医药",
      "summary": "数据或模型调用不完整，禁止推荐。",
      "ticker": "600276"
    },
    "risk_notes": [
      "必须补齐全部八维报告"
    ],
    "score": 48.36,
    "setup": "LOW_VOLUME_BREAKOUT",
    "stock_name": "恒瑞医药",
    "stop_loss": null,
    "summary": "数据或模型调用不完整，禁止推荐。",
    "target_1": null,
    "target_2": null,
    "ticker": "600276"
  },
  "report_ids": [
    "REPORT-20260715060139508620-3123c5e40fcf",
    "REPORT-20260715060203805178-a3be44d0f474",
    "REPORT-20260715060225101751-287e260a0f0f",
    "REPORT-20260715060249104275-1bf7d3834e61",
    "REPORT-20260715060257091384-9f5245b3267e",
    "REPORT-20260715060308688272-ae35acd58b4b",
    "REPORT-20260715060317435770-2d2edf4399cf",
    "REPORT-20260715060347598284-5c7bdf07af76",
    "REPORT-20260715060408578709-ea49dd7ea6f3",
    "REPORT-20260715060448114016-7d3604353ae5",
    "REPORT-20260715060503445139-4c392b8e180a"
  ],
  "risk": {
    "evidence_ids": [
      "EVD-e002fa33758068be",
      "EVD-f99a9fd1ae0cd4a9",
      "EVD-7e82f8af6a933fd9",
      "EVD-501bc402d114fd4f",
      "EVD-6329bc49d47c8900",
      "EVD-7a80095771a1ed5e",
      "EVD-67db64ca05505bb3"
    ],
    "risk_penalty": 6,
    "summary": "恒瑞医药在创新药板块情绪带动下放量上涨，但技术面存在冲高回落和60日均线压力，短期超买；基本面估值已处历史高位（对应2026年PE近40倍），而ROE偏低，业绩对BD首付款依赖度较高；板块情绪尚处发酵早期，缺乏直接公司催化剂，且龙虎榜数据缺失，资金性质不明。整体看，上行空间受限，回调风险较大。",
    "veto": false
  }
}